文献速递炎症性肠病

Etrasimod治疗轻中度活动性溃疡性结肠炎的II期GLADIATOR试验疗效与安全性

The Efficacy and Safety of Etrasimod in Mildly to Moderately Active Ulcerative Colitis: Results From the Phase II GLADIATOR Trial.
PubMed 文献 · Clin Gastroenterol Hepatol · 2026-06-04

GLADIATOR是一项II期双盲持续治疗试验,评估Etrasimod 2mg每日一次对改良Mayo评分4-6分的轻中度活动性溃疡性结肠炎患者的疗效与安全性,主要终点第52周临床缓解未达到统计学显著。事后分析显示ELEVATE UCIII期项目中类似亚组接受Etrasimod者临床缓解比例高于安慰剂。

要点

  • GLADIATOR主要终点未达到,第52周临床缓解率Etrasimod组26.0% vs 安慰剂组18.3%,差异无统计学意义。
  • Etrasimod总体耐受性良好,安全性特征与已知安全谱一致。
  • ELEVATE UCIII期项目中改良Mayo评分4-6分的类似亚组,Etrasimod组临床缓解比例高于安慰剂组。

核心结论

  • GLADIATOR试验主要终点未达到,但改良Mayo评分4-6分人群的总体数据支持Etrasimod在活动性溃疡性结肠炎中的正向获益-风险特征。

研究设计与样本

  • GLADIATOR为II期双盲持续治疗试验,纳入基线改良Mayo评分4-6分、内镜子评分≥2分且直肠出血子评分≥1分的成人溃疡性结肠炎患者。
  • 患者按2:1随机接受Etrasimod 2mg或安慰剂每日一次治疗52周,随机分层因素为生物制剂/JAK抑制剂使用经验和基线糖皮质激素使用。
  • 主要终点为第52周达到临床缓解的患者比例,安全性在所有接受至少1剂研究药物的随机患者中评估。
  • 事后合并分析III期ELEVATE UC项目中改良Mayo评分4-6分的亚组数据。

主要发现

  • 在ELEVATE UC类似亚组中,Etrasimod组第52周达到临床缓解的患者比例高于安慰剂组。
  • Etrasimod总体耐受性良好,安全性发现与已知安全谱一致。

临床怎么用

  • 对于轻中度活动性溃疡性结肠炎患者,Etrasimod可作为考虑选项之一,但需结合GLADIATOR主要终点未达到及ELEVATE UC亚组数据综合评估获益与风险。

局限性

  • GLADIATOR主要终点未达到统计学显著性,ELEVATE UC亚组分析为事后分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Etrasimod is an approved, oral, once-daily, selective sphingosine 1-phosphate receptor modulator with efficacy and safety in moderately to severely active ulcerative colitis demonstrated in the ELEVATE UC program. GLADIATOR evaluated etrasimod efficacy and safety in adults with mildly to moderately active ulcerative colitis. METHODS: GLADIATOR was a phase II, double-blind, treat-through trial. Patients with baseline modified Mayo score 4 to 6, endoscopic subscore ≥2, and rectal bleeding subscore ≥1 were randomized (2:1; stratified by biologic/Janus kinase inhibitor experience and baseline corticosteroid use) to etrasimod 2 mg or placebo once daily (52 weeks). The primary endpoint was the proportion of patients achieving clinical remission at week 52. Safety was assessed throughout in all randomized patients receiving ≥1 study treatment dose. Pooled post hoc phase III ELEVATE UC modified Mayo score 4 to 6 subpopulation data were also analyzed. RESULTS: GLADIATOR's primary endpoint was not met, although a numerically greater proportion of patients receiving etrasimod vs placebo achieved clinical remission at week 52 (26.0% vs 18.3%; placebo-adjusted percentage difference: 7.4; 95% confidence interval, -5.2 to 19.9; P = .25). In the similar ELEVATE UC subpopulation, more patients receiving etrasimod vs placebo achieved clinical remission at week 52. Etrasimod was generally well-tolerated; safety findings were consistent with the known safety profile. CONCLUSIONS: Despite GLADIATOR not meeting its primary endpoint, the totality of modified Mayo score 4 to 6 population data from GLADIATOR and ELEVATE UC reiterates the positive benefit-risk profile of etrasimod in active ulcerative colitis, while providing insights for clinical practice and future studies in mildly to moderately active ulcerative colitis. CLINICALTRIALS: gov, Numbers: NCT04607837, NCT03945188, NCT03996369, NCT04706793.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Danese S, Goetsch M, Peyrin-Biroulet L, et al. The Efficacy and Safety of Etrasimod in Mildly to Moderately Active Ulcerative Colitis: Results From the Phase II GLADIATOR Trial. Clin Gastroenterol Hepatol. 2026. PMID: 42248437. doi:10.1016/j.cgh.2026.05.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。